Remember when Dr. Li-Meng Yan made that ominous warning about intelligence suggesting the CCP could potentially use the Winter Olympics as a vector for a hemorrhagic fever virus bioweapon?
Something extremely suspicious occurred that should raise our antennas.
According to Dr. Yan, there is already a cure for this alleged bioweapon and the CCP wants to limit its availability as much as possible. It is a Johnson & Johnson drug called Darzalex (daratumumab). According to Cancer.org, the drug is currently used to treat multiple myeloma, but Dr. Yan said the CCP discovered it is also effective against their new bioweapon.
A biopharmaceutical company called Bio-Rad has reportedly developed antibodies that inhibit daratumumab from binding to receptors in the body and stopping infection with hemorrhagic fever.
Bio-Rad's anti-daratumumab antibodies are well characterized, with ELISA protocols to help get you started with development of your anti-drug assays. https://t.co/RnawSIhxvw pic.twitter.com/fUJGttPoWd
— Bio-Rad Flow Cytometry and Antibodies (@BioRadFlowAbs) January 20, 2022
Need anti-daratumumab antibodies for anti-drug assays? Bio-Rad's recombinant, non-animal-derived, sequence defined antibodies undergo stringent quality control and provide you with security of supply. https://t.co/EyZSCpk3cb pic.twitter.com/p56eLBLVK7
— Bio-Rad Flow Cytometry and Antibodies (@BioRadFlowAbs) January 12, 2022
This will be an important article in a couple months.
Bio-Rad Introduces Anti-Daratumumab Antibodies https://t.co/n5BssMcgmu
— TheClockworkElf (@JoeRogansElf) February 15, 2022
The Scientist wrote:
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.
American Partisan added:
Daratumumab is an anti-cancer monoclonal antibody treatment and is used for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mentle cell lymphoma. It works by binding itself to “CD38”, also know as cyclic ADP ribose hydrolase (a glycoprotein) found on the surface of many immune cells (white blood cells) and is often overexpressed in multiple myeloma cells.
Isn’t it suspicious that Bio-Rad would announce antibodies that inhibit the binding ability of the drug that, according to Dr. Li-Meng Yan, easily treats hemorrhagic fever?
And around the same time Dr. Yan warned us about the CCP potentially unleashing a hemorrhagic fever virus bioweapon?
Natural News connected the dots:
As we reported, there is speculation that hemorrhagic fever may have been released during the recent Winter Olympics in Beijing. We also learned that daratumumab, a product of Johnson & Johnson (J&J), “easily treats” hemorrhagic fever.
Putting two and two together, it would appear as though Bio-Rad is planning to block the efficacy of daratumumab in people’s bodies. This would theoretically leave them prone to infection with hemorrhagic fever, assuming this is the next plandemic to hit the world.
On an intriguing side note, Bio-Rad also manufacturers COVID-19 PCR tests.
Per their website:
Bio-Rad provides a comprehensive range of products for COVID-19 diagnosis, confirmation, and antibody detection including real-time PCR, droplet digital PCR, and serological testing. Our SARS-CoV-2 testing solutions span the full course of the viral infection, with options from active infection testing to post-infection antibody testing.
If Dr. Yan’s warning comes true and hemorrhagic fever virus is the next Plandemic, keep this information in your back pocket.